Loading...
UroGen Pharma Ltd.
URGN•NASDAQ
HealthcareBiotechnology
$7.02
$-0.35(-4.75%)
UroGen Pharma Ltd. (URGN) Financial Performance & Statements
Review UroGen Pharma Ltd.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns to understand its financial health and growth.
Revenue Growth
9.29%
↑ 9.29%
Operating Income Growth
-47.68%
↓ 47.68%
Net Income Growth
-24.09%
↓ 24.09%
Operating Cash Flow Growth
-26.70%
↓ 26.70%
Operating Margin
-117.51%
↓ 117.51%
Gross Margin
89.68%
↑ 89.68%
Net Profit Margin
-150.68%
↓ 150.68%
ROE
-97486.62%
↓ 97486.62%
ROIC
-52.50%
↓ 52.50%
UroGen Pharma Ltd. (URGN) Financial Statements
Explore quarterly and annual reports including balance sheet, income statement, cash flow for UroGen Pharma Ltd. stock.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $24.57M | $25.20M | $21.85M | $18.78M |
| Cost of Revenue | $2.47M | $2.45M | $2.23M | $1.73M |
| Gross Profit | $22.09M | $22.75M | $19.62M | $17.05M |
| Gross Profit Ratio | $0.90 | $0.90 | $0.90 | $0.91 |
| R&D Expenses | $14.89M | $11.36M | $15.40M | $15.49M |
| SG&A Expenses | $34.86M | $28.94M | $30.06M | $27.30M |
| Operating Expenses | $49.75M | $40.30M | $45.46M | $42.79M |
| Total Costs & Expenses | $52.22M | $42.75M | $47.69M | $44.52M |
| Interest Income | $2.81M | $2.76M | $1.72M | $1.80M |
| Interest Expense | $3.89M | $2.72M | $3.46M | $2.45M |
| Depreciation & Amortization | $306000.00 | $266000.00 | $263000.00 | $351000.00 |
| EBITDA | -$24.60M | -$14.68M | -$25.58M | -$25.39M |
| EBITDA Ratio | -$1.002 | -$0.58 | -$1.17 | -$1.35 |
| Operating Income | -$27.66M | -$17.55M | -$25.84M | -$25.74M |
| Operating Income Ratio | -$1.13 | -$0.70 | -$1.18 | -$1.37 |
| Other Income/Expenses (Net) | -$7.21M | -$6.04M | -$7.53M | -$6.49M |
| Income Before Tax | -$34.86M | -$23.58M | -$33.37M | -$32.23M |
| Income Before Tax Ratio | -$1.42 | -$0.94 | -$1.53 | -$1.72 |
| Income Tax Expense | $2.65M | $91000.00 | $38000.00 | $54000.00 |
| Net Income | -$37.51M | -$23.67M | -$33.40M | -$32.29M |
| Net Income Ratio | -$1.53 | -$0.94 | -$1.53 | -$1.72 |
| EPS | -$0.87 | -$0.55 | -$0.91 | -$0.97 |
| Diluted EPS | -$0.87 | -$0.55 | -$0.91 | -$0.97 |
| Weighted Avg Shares Outstanding | $47.03M | $43.10M | $36.82M | $33.38M |
| Weighted Avg Shares Outstanding (Diluted) | $47.03M | $43.10M | $36.82M | $33.38M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan